{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T23:55:04Z","timestamp":1793058904915,"version":"4.5.0"},"reference-count":142,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archives of Cardiovascular Diseases"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.acvd.2024.02.004","type":"journal-article","created":{"date-parts":[[2024,4,23]],"date-time":"2024-04-23T07:09:25Z","timestamp":1713856165000},"page":"358-378","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Management of lipid variables in primary cardiovascular prevention: A position paper from the Heart, Vessels and Metabolism Group of the French Society of Cardiology"],"prefix":"10.1016","volume":"117","author":[{"given":"Fran\u00e7ois","family":"Di\u00e9vart","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Bruckert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Aboyans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sa\u00efd","family":"Bekka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franck","family":"Boccara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barthelemy","family":"Bourdon Baron Munoz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Emmerich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Farnier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Gallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Lemesle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Paillard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Schiele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serge","family":"Kownator","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.acvd.2024.02.004_bib0715","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1093\/eurheartj\/ehz962","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel","volume":"41","author":"Boren","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.acvd.2024.02.004_bib0720","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel","volume":"38","author":"Ference","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.acvd.2024.02.004_bib0725","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.acvd.2024.02.004_bib0730","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC Guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.acvd.2024.02.004_bib0735","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0140-6736(12)60367-5","article-title":"The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials","volume":"380","author":"Mihaylova","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.acvd.2024.02.004_bib0740","first-page":"CD004816","article-title":"Statins for the primary prevention of cardiovascular disease","volume":"2013","author":"Taylor","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.acvd.2024.02.004_bib0745","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1001\/jama.2016.13985","article-title":"Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis","volume":"316","author":"Silverman","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.acvd.2024.02.004_bib0750","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1001\/jama.2018.21971","article-title":"Number needed to treat: conveying the likelihood of a therapeutic effect","volume":"321","author":"Saver","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.acvd.2024.02.004_bib0755","article-title":"Impact of statin related media coverage on use of statins: interrupted time series analysis with UK primary care data","volume":"353","author":"Matthews","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.acvd.2024.02.004_bib0760","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1093\/eurheartj\/ehv641","article-title":"Negative statin-related news stories decrease statin persistence and increase myocardial infarction and cardiovascular mortality: a nationwide prospective cohort study","volume":"37","author":"Nielsen","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.acvd.2024.02.004_bib0765","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.acvd.2013.06.053","article-title":"Evaluation of the impact of the recent controversy over statins in France: the EVANS study","volume":"106","author":"Saib","year":"2013","journal-title":"Arch Cardiovasc Dis"},{"key":"10.1016\/j.acvd.2024.02.004_bib0770","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s11883-020-00853-9","article-title":"Statins in a distorted mirror of media","volume":"22","author":"Nelson","year":"2020","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.acvd.2024.02.004_bib0775","series-title":"Corruptions et cr\u00e9dulit\u00e9 en m\u00e9decine\u00a0: stop aux statines et autres dangers","author":"Even","year":"2015"},{"key":"10.1016\/j.acvd.2024.02.004_bib0780","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1093\/eurjpc\/zwab067","article-title":"Cardiovascular risk stratification by coronary computed tomography angiography imaging: current state-of-the-art","volume":"29","author":"Antonopoulos","year":"2022","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.acvd.2024.02.004_bib0785","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/ehjci\/jeac137","article-title":"Pre-screening to guide coronary artery calcium scoring for early identification of high-risk individuals in the general population","volume":"24","author":"Ties","year":"2022","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"10.1016\/j.acvd.2024.02.004_bib0790","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1016\/j.respe.2018.01.010","article-title":"Cholest\u00e9rol LDL moyen et pr\u00e9valence de l\u2019hypercholest\u00e9rol\u00e9mie LDL chez les adultes en France en 2015. \u00c9tude Esteban","volume":"66","author":"Lecoffre","year":"2018","journal-title":"Rev Epidemiol Sante Publique"},{"key":"10.1016\/j.acvd.2024.02.004_bib0795","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/eurjpc\/zwaa047","article-title":"EU-wide cross-sectional observational study of lipid-modifying therapy use in secondary and primary care: the DA VINCI study","volume":"28","author":"Ray","year":"2021","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.acvd.2024.02.004_bib0800","series-title":"La v\u00e9rit\u00e9 sur le cholest\u00e9rol","author":"Even","year":"2013"},{"key":"10.1016\/j.acvd.2024.02.004_bib0805","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.acvd.2016.05.002","article-title":"Impact of a public media event on the use of statins in the French population","volume":"110","author":"Bezin","year":"2017","journal-title":"Arch Cardiovasc Dis"},{"key":"10.1016\/j.acvd.2024.02.004_bib0810","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.1093\/eurheartj\/eht295","article-title":"Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences","volume":"34","author":"Chowdhury","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.acvd.2024.02.004_bib0815","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.amjmed.2011.12.013","article-title":"Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376,162 patients","volume":"125","author":"Naderi","year":"2012","journal-title":"Am J Med"},{"key":"10.1016\/j.acvd.2024.02.004_bib0820","doi-asserted-by":"crossref","first-page":"e0191817","DOI":"10.1371\/journal.pone.0191817","article-title":"Patient-reported adherence to statin therapy, barriers to adherence, and perceptions of cardiovascular risk","volume":"13","author":"Fung","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.acvd.2024.02.004_bib0825","first-page":"51","article-title":"Adherence to statins in primary prevention: yearly adherence changes and outcomes","volume":"20","author":"Slejko","year":"2014","journal-title":"J Manag Care Pharm"},{"key":"10.1016\/j.acvd.2024.02.004_bib0830","doi-asserted-by":"crossref","first-page":"3213","DOI":"10.1093\/eurheartj\/ehac015","article-title":"Prevalence of statin intolerance: a meta-analysis","volume":"43","author":"Bytyci","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.acvd.2024.02.004_bib0835","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1161\/CIRCULATIONAHA.112.136101","article-title":"Effect of statins on skeletal muscle function","volume":"127","author":"Parker","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.acvd.2024.02.004_bib0840","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJM199901143400207","article-title":"Atherosclerosis\u00a0\u2013\u00a0an inflammatory disease","volume":"340","author":"Ross","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acvd.2024.02.004_bib0845","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1146\/annurev-pathol-020712-163936","article-title":"The influence of innate and adaptive immune responses on atherosclerosis","volume":"9","author":"Witztum","year":"2014","journal-title":"Annu Rev Pathol"},{"key":"10.1016\/j.acvd.2024.02.004_bib0850","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1056\/NEJMra2000317","article-title":"Atherosclerotic plaque healing","volume":"383","author":"Vergallo","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acvd.2024.02.004_bib0855","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1161\/01.RES.27.1.59","article-title":"Regression of coronary atheromatosis in rhesus monkeys","volume":"27","author":"Armstrong","year":"1970","journal-title":"Circ Res"},{"key":"10.1016\/j.acvd.2024.02.004_bib0860","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/0014-4800(84)90011-X","volume":"41","author":"Clarkson","year":"1984","journal-title":"Exp Mol Pathol"},{"key":"10.1016\/j.acvd.2024.02.004_bib0865","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1161\/01.ATV.4.4.341","article-title":"Studies of hypercholesterolemia in the nonhuman primate. II. Fatty streak conversion to fibrous plaque","volume":"4","author":"Faggiotto","year":"1984","journal-title":"Arteriosclerosis"},{"key":"10.1016\/j.acvd.2024.02.004_bib0870","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/j.1749-6632.1976.tb43368.x","article-title":"Studies of regression of advanced atherosclerosis in experimental animals and man","volume":"275","author":"Wissler","year":"1976","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.acvd.2024.02.004_bib0875","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJM199011083231901","article-title":"Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B","volume":"323","author":"Brown","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acvd.2024.02.004_bib0880","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1161\/01.CIR.87.6.1781","article-title":"Lipid lowering and plaque regression. New insights into prevention of plaque disruption and clinical events in coronary disease","volume":"87","author":"Brown","year":"1993","journal-title":"Circulation"},{"key":"10.1016\/j.acvd.2024.02.004_bib0885","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0733-8651(05)70258-7","article-title":"Pathophysiology of plaque rupture and the concept of plaque stabilization","volume":"14","author":"Shah","year":"1996","journal-title":"Cardiol Clin"},{"key":"10.1016\/j.acvd.2024.02.004_bib0890","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1126\/science.1059344","article-title":"Structural mechanism for statin inhibition of HMG-CoA reductase","volume":"292","author":"Istvan","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.acvd.2024.02.004_bib0895","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.phrs.2014.03.002","article-title":"The pharmacology of statins","volume":"88","author":"Sirtori","year":"2014","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.acvd.2024.02.004_bib0900","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.tcm.2019.01.001","article-title":"Effect of statins on atherosclerotic plaque","volume":"29","author":"Almeida","year":"2019","journal-title":"Trends Cardiovasc Med"},{"key":"10.1016\/j.acvd.2024.02.004_bib0905","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1001\/jama.2016.16951","article-title":"Effect of evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV randomized clinical trial","volume":"316","author":"Nicholls","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.acvd.2024.02.004_bib0910","doi-asserted-by":"crossref","first-page":"C7","DOI":"10.1016\/j.jacc.2005.09.068","article-title":"Pathogenesis of atherosclerosis","volume":"47","author":"Falk","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.acvd.2024.02.004_bib0915","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1161\/ATVBAHA.119.311574","article-title":"Plaque calcification: do lipoproteins have a role?","volume":"39","author":"Akers","year":"2019","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.acvd.2024.02.004_bib0920","first-page":"B53","article-title":"Cholesterol and risk of coronary heart disease and mortality in men","volume":"34","author":"Kannel","year":"1988","journal-title":"Clin Chem"},{"key":"10.1016\/j.acvd.2024.02.004_bib0925","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1016\/S0140-6736(07)61778-4","article-title":"Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths","volume":"370","author":"Lewington","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.acvd.2024.02.004_bib0930","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1161\/01.CIR.91.8.2274","article-title":"Cholesterol reduction yields clinical benefit. A new look at old data","volume":"91","author":"Gould","year":"1995","journal-title":"Circulation"},{"key":"10.1016\/j.acvd.2024.02.004_bib0935","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1161\/01.CIR.97.10.946","article-title":"Cholesterol reduction yields clinical benefit: impact of statin trials","volume":"97","author":"Gould","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.acvd.2024.02.004_bib0940","first-page":"1383","article-title":"Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)","volume":"344","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.acvd.2024.02.004_bib0945","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.acvd.2024.02.004_bib0950","first-page":"CD004816","article-title":"Statins for the primary prevention of cardiovascular disease","author":"Taylor","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.acvd.2024.02.004_bib0955","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1016\/S0140-6736(10)60656-3","article-title":"Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis","volume":"375","author":"Jun","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.acvd.2024.02.004_bib0960","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.g4379","article-title":"Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients","volume":"349","author":"Keene","year":"2014","journal-title":"BMJ"},{"key":"10.1016\/j.acvd.2024.02.004_bib0965","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1056\/NEJMoa1701131","article-title":"Cognitive function in a randomized trial of evolocumab","volume":"377","author":"Giugliano","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acvd.2024.02.004_bib0970","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1161\/01.CIR.55.5.767","article-title":"HDL cholesterol and other lipids in coronary heart disease. The cooperative lipoprotein phenotyping study","volume":"55","author":"Castelli","year":"1977","journal-title":"Circulation"},{"key":"10.1016\/j.acvd.2024.02.004_bib0975","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1001\/jama.2009.1619","article-title":"Major lipids, apolipoproteins, and risk of vascular disease","volume":"302","author":"Di Angelantonio","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.acvd.2024.02.004_bib0980","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/j.jacc.2016.08.038","article-title":"High-density lipoprotein cholesterol and cause-specific mortality in individuals without previous cardiovascular conditions: the CANHEART study","volume":"68","author":"Ko","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.acvd.2024.02.004_bib0985","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1093\/eurjpc\/zwab230","article-title":"High-density lipoprotein cholesterol and cardiovascular mortality: a prospective cohort study among 15.8 million adults","volume":"29","author":"Yi","year":"2022","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.acvd.2024.02.004_bib0990","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.b92","article-title":"Association between change in high-density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis","volume":"338","author":"Briel","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.acvd.2024.02.004_bib0995","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1001\/jama.285.12.1585","article-title":"Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial","volume":"285","author":"Robins","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.acvd.2024.02.004_bib1000","first-page":"89","article-title":"The independent relationship between triglycerides and coronary heart disease","volume":"5","author":"Morrison","year":"2009","journal-title":"Vasc Health Risk Manag"},{"key":"10.1016\/j.acvd.2024.02.004_bib1005","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1056\/NEJMoa1203859","article-title":"n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia","volume":"367","author":"Bosch","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acvd.2024.02.004_bib1010","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acvd.2024.02.004_bib1015","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1136\/svn-2020-000726","article-title":"Cumulative burden of lipid profiles predict future incidence of ischaemic stroke and residual risk","volume":"6","author":"Dai","year":"2021","journal-title":"Stroke Vasc Neurol"},{"key":"10.1016\/j.acvd.2024.02.004_bib1020","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/j.jacc.2018.06.046","article-title":"Impact of lipids on cardiovascular health: JACC health promotion series","volume":"72","author":"Ference","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.acvd.2024.02.004_bib1025","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1001\/jamacardio.2021.3508","article-title":"Association between cumulative low-density lipoprotein cholesterol exposure during young adulthood and middle age and risk of cardiovascular events","volume":"6","author":"Zhang","year":"2021","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.acvd.2024.02.004_bib1030","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1016\/j.jacc.2021.09.004","article-title":"Familial hypercholesterolemia: JACC focus seminar 4\/4","volume":"78","author":"Brandts","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.acvd.2024.02.004_bib1035","doi-asserted-by":"crossref","first-page":"e013225","DOI":"10.1161\/JAHA.119.013225","article-title":"Diagnosis and treatment of heterozygous familial hypercholesterolemia","volume":"8","author":"McGowan","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.acvd.2024.02.004_bib1040","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/eht273","article-title":"Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society","volume":"34","author":"Nordestgaard","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.acvd.2024.02.004_bib1045","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa1910355","article-title":"A comparison of two LDL cholesterol targets after ischemic stroke","volume":"382","author":"Amarenco","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acvd.2024.02.004_bib1050","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1016\/S0140-6736(16)31357-5","article-title":"Interpretation of the evidence for the efficacy and safety of statin therapy","volume":"388","author":"Collins","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.acvd.2024.02.004_bib1055","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1093\/eurheartj\/ehad192","article-title":"2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes","volume":"44","author":"Marx","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.acvd.2024.02.004_bib1060","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1093\/eurheartj\/ehad260","article-title":"SCORE2-Diabetes: 10-year cardiovascular risk estimation in type 2 diabetes in Europe","volume":"44","author":"the ESC Cardiovascular Risk Collaboration","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.acvd.2024.02.004_bib1065","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1093\/eurheartj\/ehab309","article-title":"SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe","volume":"42","author":"the ESC Cardiovascular Risk Collaboration","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.acvd.2024.02.004_bib1070","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/S0140-6736(22)01349-6","article-title":"Autoimmune diseases and cardiovascular risk: a population-based study on 19 autoimmune diseases and 12 cardiovascular diseases in 22 million individuals in the UK","volume":"400","author":"Conrad","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.acvd.2024.02.004_bib1075","doi-asserted-by":"crossref","first-page":"e219211","DOI":"10.1001\/jamanetworkopen.2021.9211","article-title":"Qualitative exploration of barriers to statin adherence and lipid control: a secondary analysis of a randomized clinical trial","volume":"4","author":"Barankay","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.acvd.2024.02.004_bib1080","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1007\/s11606-016-3858-0","article-title":"Patient and partner feedback reports to improve statin medication adherence: a randomized control trial","volume":"32","author":"Reddy","year":"2017","journal-title":"J Gen Intern Med"},{"key":"10.1016\/j.acvd.2024.02.004_bib1085","doi-asserted-by":"crossref","first-page":"e0146272","DOI":"10.1371\/journal.pone.0146272","article-title":"Understanding statin non-adherence: knowing which perceptions and experiences matter to different patients","volume":"11","author":"Wouters","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.acvd.2024.02.004_bib1090","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.acvd.2008.08.006","article-title":"Assessment of lipid-lowering treatment in France\u00a0\u2013\u00a0the CEPHEUS study","volume":"101","author":"Ferrieres","year":"2008","journal-title":"Arch Cardiovasc Dis"},{"key":"10.1016\/j.acvd.2024.02.004_bib1095","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s12933-015-0296-y","article-title":"Patients with coronary artery disease and diabetes need improved management: a report from the EUROASPIRE IV survey: a registry from the EuroObservational Research Programme of the European Society of Cardiology","volume":"14","author":"Gyberg","year":"2015","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.acvd.2024.02.004_bib1100","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJMoa1212914","article-title":"Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes","volume":"369","author":"Wing","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acvd.2024.02.004_bib1105","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa1110294","article-title":"Lifestyle change and mobility in obese adults with type 2 diabetes","volume":"366","author":"Rejeski","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acvd.2024.02.004_bib1110","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.2337\/dc10-2415","article-title":"Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes","volume":"34","author":"Wing","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.acvd.2024.02.004_bib1115","doi-asserted-by":"crossref","first-page":"e34","DOI":"10.1056\/NEJMoa1800389","article-title":"Primary prevention of cardiovascular disease with a mediterranean diet supplemented with extra-virgin olive oil or nuts","volume":"378","author":"Estruch","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acvd.2024.02.004_bib1120","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1016\/S0140-6736(22)00122-2","article-title":"Long-term secondary prevention of cardiovascular disease with a Mediterranean diet and a low-fat diet (CORDIOPREV): a randomised controlled trial","volume":"399","author":"Delgado-Lista","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.acvd.2024.02.004_bib1125","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1093\/ajcn\/65.3.823","article-title":"Individual variability in lipoprotein cholesterol response to National Cholesterol Education Program Step 2 diets","volume":"65","author":"Schaefer","year":"1997","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.acvd.2024.02.004_bib1130","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.atherosclerosis.2021.03.024","article-title":"Does variation in serum LDL-cholesterol response to dietary fatty acids help explain the controversy over fat quality and cardiovascular disease risk?","volume":"328","author":"Griffin","year":"2021","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.acvd.2024.02.004_bib1135","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1161\/01.ATV.3.4.349","article-title":"Variability in individual serum cholesterol response to change in diet","volume":"3","author":"Jacobs","year":"1983","journal-title":"Arteriosclerosis"},{"key":"10.1016\/j.acvd.2024.02.004_bib1140","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1001\/jama.2011.1202","article-title":"Effect of a dietary portfolio of cholesterol-lowering foods given at 2 levels of intensity of dietary advice on serum lipids in hyperlipidemia: a randomized controlled trial","volume":"306","author":"Jenkins","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.acvd.2024.02.004_bib1145","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.atherosclerosissup.2019.08.023","article-title":"The role of red yeast rice (RYR) supplementation in plasma cholesterol control: a review and expert opinion","volume":"39","author":"Banach","year":"2019","journal-title":"Atheroscler Suppl"},{"key":"10.1016\/j.acvd.2024.02.004_bib1150","doi-asserted-by":"crossref","first-page":"606959","DOI":"10.3389\/fmicb.2020.606959","article-title":"Perspectives on functional red mold rice: functional ingredients, production, and application","volume":"11","author":"Yanli","year":"2020","journal-title":"Front Microbiol"},{"key":"10.1016\/j.acvd.2024.02.004_bib1155","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1001\/archinternmed.2010.382","article-title":"Marked variability of monacolin levels in commercial red yeast rice products: buyer beware","volume":"170","author":"Gordon","year":"2010","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.acvd.2024.02.004_bib1160","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.nut.2018.10.021","article-title":"Dietary habits and adherence to dietary recommendations in patients with type 1 and type 2 diabetes compared with the general population in Denmark","volume":"61","author":"Ewers","year":"2019","journal-title":"Nutrition"},{"key":"10.1016\/j.acvd.2024.02.004_bib1165","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/j.1753-4887.2008.00025.x","article-title":"Changing dietary habits of ethnic groups in Europe and implications for health","volume":"66","author":"Gilbert","year":"2008","journal-title":"Nutr Rev"},{"key":"10.1016\/j.acvd.2024.02.004_bib1170","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s12916-021-02011-7","article-title":"Adherence to international dietary recommendations in association with all-cause mortality and fatal and non-fatal cardiovascular disease risk: a prospective analysis of UK Biobank participants","volume":"19","author":"Kebbe","year":"2021","journal-title":"BMC Med"},{"key":"10.1016\/j.acvd.2024.02.004_bib1175","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1016\/S0140-6736(20)32233-9","article-title":"Elevated LDL cholesterol and increased risk of myocardial infarction and atherosclerotic cardiovascular disease in individuals aged 70\u2013100 years: a contemporary primary prevention cohort","volume":"396","author":"Mortensen","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.acvd.2024.02.004_bib1180","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/S0140-6736(02)11600-X","article-title":"Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial","volume":"360","author":"Shepherd","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.acvd.2024.02.004_bib1185","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/S0140-6736(20)32332-1","article-title":"Efficacy and safety of lowering LDL cholesterol in older patients: a systematic review and meta-analysis of randomised controlled trials","volume":"396","author":"Gencer","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.acvd.2024.02.004_bib1190","doi-asserted-by":"crossref","DOI":"10.1093\/ageing\/afab282","article-title":"Clinical trials in older people","volume":"51","author":"Pitkala","year":"2022","journal-title":"Age Ageing"},{"key":"10.1016\/j.acvd.2024.02.004_bib1195","doi-asserted-by":"crossref","first-page":"3856","DOI":"10.1093\/eurheartj\/ehab468","article-title":"Frailty and cardiovascular outcomes in the National Health and Aging Trends Study","volume":"42","author":"Damluji","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.acvd.2024.02.004_bib1200","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1161\/ATVBAHA.108.179796","article-title":"Status of women in cardiovascular clinical trials","volume":"29","author":"Kim","year":"2009","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.acvd.2024.02.004_bib1205","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/S0140-6736(14)61368-4","article-title":"Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials","volume":"385","author":"Fulcher","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.acvd.2024.02.004_bib1210","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.2174\/138161209787846946","article-title":"The role of statins for the primary and secondary prevention of coronary heart disease in women","volume":"15","author":"Tziomalos","year":"2009","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.acvd.2024.02.004_bib1215","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s40256-015-0111-x","article-title":"Statins and aspirin: do they really work in women?","volume":"15","author":"Desai","year":"2015","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.acvd.2024.02.004_bib1220","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","article-title":"MRC\/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial","volume":"360","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.acvd.2024.02.004_bib1225","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.jacc.2011.09.067","article-title":"Meta-analysis of statin effects in women versus men","volume":"59","author":"Kostis","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.acvd.2024.02.004_bib1230","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1161\/CIRCRESAHA.115.306249","article-title":"Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease: new insights from epidemiology, genetics, and biology","volume":"118","author":"Nordestgaard","year":"2016","journal-title":"Circ Res"},{"key":"10.1016\/j.acvd.2024.02.004_bib1235","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1210\/er.2018-00184","article-title":"The forgotten lipids: triglycerides, remnant cholesterol, and atherosclerotic cardiovascular disease risk","volume":"40","author":"Sandesara","year":"2019","journal-title":"Endocr Rev"},{"key":"10.1016\/j.acvd.2024.02.004_bib1240","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehz785","article-title":"Clinical review on triglycerides","volume":"41","author":"Laufs","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.acvd.2024.02.004_bib1245","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1093\/eurheartj\/ehy169","article-title":"Rare SCARB1 mutations associate with high-density lipoprotein cholesterol but not with coronary artery disease","volume":"39","author":"Helgadottir","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.acvd.2024.02.004_bib1250","doi-asserted-by":"crossref","first-page":"3399","DOI":"10.1210\/jc.2012-2185","article-title":"Approach to the patient with extremely low HDL-cholesterol","volume":"97","author":"Rader","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.acvd.2024.02.004_bib1255","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/S0140-6736(12)60312-2","article-title":"Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study","volume":"380","author":"Voight","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.acvd.2024.02.004_bib1260","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1093\/eurheartj\/ehx274","article-title":"HDL cholesterol concentration or HDL function: which matters?","volume":"38","author":"Barter","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.acvd.2024.02.004_bib1265","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1093\/eurheartj\/ehy182","article-title":"Adverse effects of statin therapy: perception vs. the evidence\u00a0\u2013\u00a0focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract","volume":"39","author":"Mach","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.acvd.2024.02.004_bib1270","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1161\/ATV.0000000000000073","article-title":"Statin safety and associated adverse events: a scientific statement from the American Heart Association","volume":"39","author":"Newman","year":"2019","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.acvd.2024.02.004_bib1275","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/eurheartj\/ehv043","article-title":"Statin-associated muscle symptoms: impact on statin therapy\u00a0\u2013\u00a0European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management","volume":"36","author":"Stroes","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.acvd.2024.02.004_bib1280","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1016\/j.jacc.2016.02.071","article-title":"Statin-associated side effects","volume":"67","author":"Thompson","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.acvd.2024.02.004_bib1285","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/j.jacc.2016.12.036","article-title":"Statin intolerance and risk of coronary heart events and all-cause mortality following myocardial infarction","volume":"69","author":"Serban","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.acvd.2024.02.004_bib1290","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s10557-005-5686-z","article-title":"Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients\u00a0\u2013\u00a0the PRIMO study","volume":"19","author":"Bruckert","year":"2005","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.acvd.2024.02.004_bib1295","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1016\/S0140-6736(17)31075-9","volume":"389","author":"Gupta","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.acvd.2024.02.004_bib1300","article-title":"Statin treatment and muscle symptoms: series of randomised, placebo controlled n-of-1 trials","volume":"372","author":"Herrett","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.acvd.2024.02.004_bib1305","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1056\/NEJMc2031173","article-title":"N-of-1 trial of a statin, placebo, or no treatment to assess side effects","volume":"383","author":"Wood","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acvd.2024.02.004_bib1310","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1016\/j.jacl.2014.03.004","article-title":"An assessment by the Statin Muscle Safety Task Force: 2014 update","volume":"8","author":"Rosenson","year":"2014","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.acvd.2024.02.004_bib1315","series-title":"Sant\u00e9 2030\u00a0: une analyse prospective de l\u2019innovation en sant\u00e9","year":"2019"},{"key":"10.1016\/j.acvd.2024.02.004_bib1320","series-title":"Handbook of health behavior research II","first-page":"190","article-title":"The history and meaning of patient compliance as an ideology","author":"Trostle","year":"1997"},{"key":"10.1016\/j.acvd.2024.02.004_bib1325","first-page":"291","article-title":"Medication compliance: concepts and determinants","volume":"4","author":"Cottin","year":"2012","journal-title":"Arch Cardiovasc Dis Suppl"},{"key":"10.1016\/j.acvd.2024.02.004_bib1330","series-title":"L\u2019observance aux traitements contre le VIH\/sida\u00a0: mesures, d\u00e9terminants, \u00e9volution","first-page":"5","article-title":"De la recherche \u00e0 l\u2019intervention sur l\u2019observance th\u00e9rapeutique\u00a0: contributions et perspectives des sciences sociales","author":"Morin","year":"2001"},{"key":"10.1016\/j.acvd.2024.02.004_bib1335","first-page":"358","article-title":"[Observance during clinical trials in HIV infection. A discontinuity between patient history and trial logic]","volume":"26","author":"Munzenberger","year":"1997","journal-title":"Presse Med"},{"key":"10.1016\/j.acvd.2024.02.004_bib1340","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1046\/j.1365-2648.2003.02712.x","article-title":"Health belief model and reversal theory: a comparative analysis","volume":"43","author":"Finfgeld","year":"2003","journal-title":"J Adv Nurs"},{"key":"10.1016\/j.acvd.2024.02.004_bib1345","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1177\/109019817400200403","article-title":"Historical origins of the health belief model","volume":"2","author":"Rosenstock","year":"1974","journal-title":"Health Educ Monogr"},{"key":"10.1016\/j.acvd.2024.02.004_bib1350","series-title":"Les comportements dans le domaine de la sant\u00e9\u00a0: comprendre pour mieux intervenir","author":"Godin","year":"2012"},{"key":"10.1016\/j.acvd.2024.02.004_bib1355","doi-asserted-by":"crossref","first-page":"87","DOI":"10.4278\/0890-1171-11.2.87","article-title":"The theory of planned behavior: a review of its applications to health-related behaviors","volume":"11","author":"Godin","year":"1996","journal-title":"Am J Health Promot"},{"key":"10.1016\/j.acvd.2024.02.004_bib1360","series-title":"Effective health risk messages: a step-by-step guide","author":"Witte","year":"2001"},{"key":"10.1016\/j.acvd.2024.02.004_bib1365","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1345\/aph.1H153","article-title":"Relationships between beliefs about medications and nonadherence to prescribed chronic medications","volume":"40","author":"Phatak","year":"2006","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.acvd.2024.02.004_bib1370","first-page":"233","article-title":"Pertinence des messages de sant\u00e9\u00a0: \u00e9tude sur les temps de lecture des phrases \u00e0 messages pr\u00e9ventifs","volume":"476","author":"Gnesa","year":"2005","journal-title":"B Psychol"},{"key":"10.1016\/j.acvd.2024.02.004_bib1375","series-title":"Belief, attitude, intention, and behavior: an introduction to theory and research","author":"Fishbein","year":"1975"},{"key":"10.1016\/j.acvd.2024.02.004_bib1380","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1080\/08870446.2011.613995","article-title":"The theory of planned behaviour: reactions and reflections","volume":"26","author":"Ajzen","year":"2011","journal-title":"Psychol Health"},{"key":"10.1016\/j.acvd.2024.02.004_bib1385","series-title":"Health psychology","first-page":"75","article-title":"Improving patients\u2019 understanding, recall, satisfaction and compliance","author":"Ley","year":"1995"},{"key":"10.1016\/j.acvd.2024.02.004_bib1390","first-page":"117","article-title":"L\u2019appr\u00e9ciation psychosociale de l\u2019observance dans l\u2019asthme s\u00e9v\u00e8re\u00a0: confrontation de donn\u00e9es subjectives issues d\u2019une consultation m\u00e9dicale \u00e0 une mesure objective","volume":"82","author":"Hamili","year":"2009","journal-title":"Cah Int Psychol Soc"},{"key":"10.1016\/j.acvd.2024.02.004_bib1395","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1192\/bjp.160.1.83","article-title":"Out-patient compliance with antidepressant medication","volume":"160","author":"Myers","year":"1992","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.acvd.2024.02.004_bib1400","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s00592-020-01628-z","article-title":"The association of the level of self-care on adherence to treatment in patients diagnosed with type 2 diabetes","volume":"58","author":"Krzeminska","year":"2021","journal-title":"Acta Diabetol"},{"key":"10.1016\/j.acvd.2024.02.004_bib1405","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/2980250","article-title":"Determinants of poor treatment adherence among patients with type 2 diabetes and limited health literacy: a scoping review","volume":"2022","author":"Pourhabibi","year":"2022","journal-title":"J Diabetes Res"},{"issue":"Suppl.\u00a02","key":"10.1016\/j.acvd.2024.02.004_bib1410","doi-asserted-by":"crossref","first-page":"S130","DOI":"10.1007\/s10072-007-0765-5","article-title":"The patient-physician relationship in the approach to therapeutic management","volume":"28","author":"Manzoni","year":"2007","journal-title":"Neurol Sci"},{"key":"10.1016\/j.acvd.2024.02.004_bib1415","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s10880-022-09844-1","article-title":"The effects of physicians\u2019 communication and empathy ability on physician-patient relationship from physicians\u2019 and patients\u2019 perspectives","volume":"29","author":"Wang","year":"2022","journal-title":"J Clin Psychol Med Settings"},{"key":"10.1016\/j.acvd.2024.02.004_bib1420","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1046\/j.1525-1497.2002.10640.x","article-title":"The sociophysiology of caring in the doctor-patient relationship","volume":"17","author":"Adler","year":"2002","journal-title":"J Gen Intern Med"}],"container-title":["Archives of Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1875213624000500?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1875213624000500?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T14:04:10Z","timestamp":1746108250000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1875213624000500"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":142,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S1875213624000500"],"URL":"https:\/\/doi.org\/10.1016\/j.acvd.2024.02.004","relation":{},"ISSN":["1875-2136"],"issn-type":[{"value":"1875-2136","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of lipid variables in primary cardiovascular prevention: A position paper from the Heart, Vessels and Metabolism Group of the French Society of Cardiology","name":"articletitle","label":"Article Title"},{"value":"Archives of Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.acvd.2024.02.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}